在MUC1耐受的结肠癌模型中，MUC1特异性免疫疗法可产生强烈的抗肿瘤反应。
MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
作者信息
Mukherjee P, Pathangey L B, Bradley J B, Tinder T L, Basu G D, Akporiaye E T, Gendler S J
机构信息
Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, United States.
出版信息
Vaccine. 2007 Feb 19;25(9):1607-18. doi: 10.1016/j.vaccine.2006.11.007. Epub 2006 Nov 16.
Abstract
A MUC1-based vaccine was used in a preclinical model of colon cancer. The trial was conducted in a MUC1-tolerant immune competent host injected with MC38 colon cancer cells expressing MUC1. The vaccine included: MHC class I-restricted MUC1 peptides, MHC class II-restricted pan-helper-peptide, unmethylated CpG oligodeoxynucleotide, and granulocyte macrophage-colony stimulating factor. Immunization was successful in breaking MUC1 self-tolerance, and in eliciting a robust anti-tumor response. The vaccine stimulated IFN-gamma-producing CD4(+) helper and CD8(+) cytotoxic T cells against MUC1 and other undefined MC38 tumor antigens. In the prophylactic setting, immunization caused complete rejection of tumor cells, while in the therapeutic regimen, tumor burden was significantly reduced.
摘要
一种基于MUC1的疫苗被用于结肠癌的临床前模型。该试验在一个对MUC1耐受的免疫功能正常宿主中进行，该宿主被注射了表达MUC1的MC38结肠癌细胞。疫苗包括：MHC I类限制性MUC1肽、MHC II类限制性泛辅助肽、未甲基化的CpG寡脱氧核苷酸和粒细胞巨噬细胞集落刺激因子。免疫成功打破了MUC1自身耐受性，并引发了强烈的抗肿瘤反应。该疫苗刺激产生IFN-γ的CD4(+)辅助性T细胞和CD8(+)细胞毒性T细胞针对MUC1和其他未明确的MC38肿瘤抗原。在预防性情况下，免疫导致肿瘤细胞完全排斥，而在治疗方案中，肿瘤负荷显著降低。
相似文献
1
MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Vaccine. 2007 Feb 19;25(9):1607-18. doi: 10.1016/j.vaccine.2006.11.007. Epub 2006 Nov 16.
2
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.
Vaccine. 2007 Sep 28;25(39-40):6965-74. doi: 10.1016/j.vaccine.2007.06.063. Epub 2007 Jul 24.
3
Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Asian Pac J Cancer Prev. 2011;12(11):2811-7.
4
Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
Clin Cancer Res. 1999 Jul;5(7):1918-24.
5
ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Vaccine. 2011 Jun 24;29(29-30):4676-86. doi: 10.1016/j.vaccine.2011.04.103. Epub 2011 May 12.
6
Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
Br J Haematol. 2015 Apr;169(1):44-56. doi: 10.1111/bjh.13245. Epub 2014 Dec 11.
7
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
J Immunol. 2001 Jun 1;166(11):6555-63. doi: 10.4049/jimmunol.166.11.6555.
8
Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine.
Oncol Rep. 2015 Oct;34(4):1795-804. doi: 10.3892/or.2015.4137. Epub 2015 Jul 20.
9
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
J Immunother. 2003 Jan-Feb;26(1):47-62. doi: 10.1097/00002371-200301000-00006.
10
Tecemotide: an antigen-specific cancer immunotherapy.
Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836.
引用本文的文献
1
Dual-functional probe for sensitive detection of MCF-7 cells and mendelian randomization analysis of MUC1 association with multiple cancers.
Sci Rep. 2025 Feb 20;15(1):6167. doi: 10.1038/s41598-025-90575-2.
2
Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.
Diagnostics (Basel). 2024 Jul 13;14(14):1512. doi: 10.3390/diagnostics14141512.
3
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer.
Discov Oncol. 2024 Jun 25;15(1):244. doi: 10.1007/s12672-024-01117-7.
4
The Role of MUC1 in Renal Cell Carcinoma.
Biomolecules. 2024 Mar 7;14(3):315. doi: 10.3390/biom14030315.
5
Vaccination and Microbiota Manipulation Approaches for Colon Cancer Prevention in Rodent Models.
Cancer Prev Res (Phila). 2023 Aug 1;16(8):429-438. doi: 10.1158/1940-6207.CAPR-23-0015.
6
Prevention of Inflammation-Driven Colon Carcinogenesis in Human MUC1 Transgenic Mice by Vaccination with DNA and Dendritic Cells.
Cancers (Basel). 2023 Mar 22;15(6):1920. doi: 10.3390/cancers15061920.
7
The Mucin Family of Proteins: Candidates as Potential Biomarkers for Colon Cancer.
Cancers (Basel). 2023 Feb 27;15(5):1491. doi: 10.3390/cancers15051491.
8
Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review.
Vaccines (Basel). 2022 Oct 16;10(10):1727. doi: 10.3390/vaccines10101727.
9
A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer.
Curr Top Med Chem. 2022;22(31):2571-2588. doi: 10.2174/1568026622666220516105049.
10
Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.
World J Gastrointest Surg. 2021 Dec 27;13(12):1567-1583. doi: 10.4240/wjgs.v13.i12.1567.
本文引用的文献
1
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Am J Clin Oncol. 2006 Aug;29(4):352-60. doi: 10.1097/01.coc.0000217877.78473.a4.
2
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Breast Cancer Res. 2006;8(3):R27. doi: 10.1186/bcr1505. Epub 2006 Jun 15.
3
Therapeutic potential of Toll-like receptor 9 activation.
Nat Rev Drug Discov. 2006 Jun;5(6):471-84. doi: 10.1038/nrd2059.
4
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
J Urol. 2006 Jul;176(1):91-5. doi: 10.1016/S0022-5347(06)00494-0.
5
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
Cancer Res. 2006 Jun 1;66(11):5910-8. doi: 10.1158/0008-5472.CAN-05-3905.
6
A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Vaccine. 2006 Apr 12;24(16):3340-52. doi: 10.1016/j.vaccine.2006.01.014. Epub 2006 Jan 19.
7
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77. doi: 10.1158/1078-0432.CCR-05-1574.
8
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Int J Cancer. 2006 Jun 1;118(11):2790-5. doi: 10.1002/ijc.21681.
9
Breaking down the barriers to cancer immunotherapy.
Nat Immunol. 2005 Dec;6(12):1207-10. doi: 10.1038/ni1205-1207.
10
Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
Expert Rev Vaccines. 2005 Jun;4(3):249-57. doi: 10.1586/14760584.4.3.249.
Zotero 插件